人血管黏附蛋白-1（VAP-1）：非酒精性和酒精性脂肪性肝病中肝细胞癌的血清水平。
Human vascular adhesion proteın-1 (VAP-1): serum levels for hepatocellular carcinoma in non-alcoholic and alcoholic fatty liver disease.
机构信息
Department of General Surgery, Yuzuncu Yil University Medical Faculty, Van, Turkey.
出版信息
World J Surg Oncol. 2010 Sep 17;8:83. doi: 10.1186/1477-7819-8-83.
BACKGROUND
The incidence of hepatocellular cancer in complicated alcoholic and non-alcoholic fatty liver diseases is on the rise in western countries as well in our country. Vascular adhesion protein-1 (VAP-1) levels have been presented as new marker. In our study protocol, we assessed the value of this serum protein, as a newly postulant biomarker for hepatocellular cancer in patients with a history of alcoholic and non-alcoholic fatty liver diseases.
METHODS
Pre-operative serum samples from 55 patients with hepatocellular cancer with a history of alcoholic and non-alcoholic fatty liver diseases and patients with cirrhosis were assessed by a quantitative sandwich ELISA using anti-VAP-1 mAbs. This technique is used to determine the levels of soluble VAP-1 (sVAP-1) in the serum.
RESULTS
sVAP-1 levels were evaluated in patients with hepatocellular cancer and liver cirrhosis. There was a significant difference in mean VAP-1 levels between groups. Serum VAP-1 levels were found higher in patients with hepatocellular cancer.
CONCLUSION
These findings indicate that the serum level of sVAP-1 might be a beneficial marker of disease activity in chronic liver diseases.
背景
在西方国家和我国，合并酒精性和非酒精性脂肪性肝病的肝细胞癌发病率呈上升趋势。血管黏附蛋白-1（VAP-1）水平被认为是一种新的标志物。在我们的研究方案中，我们评估了这种血清蛋白作为一种新的候选生物标志物在有酒精性和非酒精性脂肪性肝病病史的肝细胞癌患者中的价值。
方法
采用抗 VAP-1 mAb 的定量夹心 ELISA 法检测 55 例有酒精性和非酒精性脂肪性肝病病史的肝细胞癌患者和肝硬化患者的术前血清样本。该技术用于测定血清中可溶性 VAP-1（sVAP-1）的水平。
结果
评估了肝细胞癌和肝硬化患者的 sVAP-1 水平。组间 VAP-1 水平的平均值存在显著差异。肝细胞癌患者的血清 VAP-1 水平较高。
结论
这些发现表明，血清 sVAP-1 水平可能是慢性肝病疾病活动的有益标志物。
Zotero 插件